7 recruiting, 4 completed, 1 active not recruiting. 8 Phase 2, 4 Phase 3, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 6, Completed 2 |
| Phase 3 | 4 | Recruiting 4 |
| Not applicable | 2 | Completed 2 |
Follow Narcolepsy Type 2: new trials by email Literature Review of Narcolepsy Type 2 trials Research Report on Narcolepsy Type 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia TAK-360, Placebo - Idiopathic Hypersomnia, Narcolepsy Type 1 | Phase 2 / Phase 3 | Recruiting | Takeda | 500 | 2026-06-11 | 2026-09-18 |
| A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence cleminorexton, Placebo - Narcolepsy Type 1, Narcolepsy Type 2 | Phase 2 / Phase 3 | Recruiting | Centessa Pharmaceuticals (UK) Limited | 222 | 2026-05-29 | 2026-10-02 |
| A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 ALKS 2680 Dose 1, ALKS 2680 Dose 2, ALKS 2680 Dose 3 - Narcolepsy Type 2 | Phase 3 | Recruiting | Alkermes, Inc. | 176 | 2026-04-22 | 2026-10-07 |
| Epidemiology of Narcolepsy Type 1 and Type 2 in Spain No intervention - Narcolepsy Type 1, Narcolepsy Type 2 | Active not recruiting | Takeda | 402 | 2025-12-02 | 2026-09-01 | |
| A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia ORX750 - Narcolepsy Type 1, Narcolepsy Type 2 | Phase 2 | Recruiting | Centessa Pharmaceuticals (UK) Limited | 90 | 2025-08-12 | 2026-04-16 |
| A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) TAK-360, Placebo - Narcolepsy Type 2 | Phase 2 | Recruiting | Takeda | 88 | 2025-05-06 | 2026-10-08 |
| A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg - Narcolepsy Type 1, Narcolepsy Type 2 | Phase 2 / Phase 3 | Recruiting | Alkermes, Inc. | 786 | 2025-01-27 | 2026-10-09 |
| A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia ORX750, Placebo - Narcolepsy Type 1, Narcolepsy Type 2 | Phase 2 | Recruiting | Centessa Pharmaceuticals (UK) Limited | 248 | 2024-12-23 | 2026-04-27 |
| A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 ALKS 2680, Placebo - Narcolepsy Type 2 | Phase 2 | Completed | Alkermes, Inc. | 93 | 2024-07-26 | 2026-02-27 |
| Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence Web-based psychoeducational resource - Narcolepsy Type 1, Narcolepsy Type 2 | Not applicable | Completed | Boston Children's Hospital | 25 | 2024-04-01 | 2026-03-18 |
| Narcolepsy Nightmare Study Imagery rehearsal therapy, Targeted dream control - Narcolepsy, Narcolepsy Type 1 | Not applicable | Completed | Northwestern University | 7 | 2023-02-22 | 2026-06-30 |
| A Study of TAK-861 in Participants With Narcolepsy Type 2 Placebo, TAK-861 2 mg, TAK-861 2 mg and 5 mg - Narcolepsy Type 2 | Phase 2 | Completed | Takeda | 71 | 2023-01-09 | 2025-01-09 |
Disorders of Excessive Somnolence (5) · Idiopathic Hypersomnia (5) · Narcolepsy (5) · Sleep Wake Disorders (4) · Cataplexy (1) · Dyssomnias (1) · Mental Disorders (1) · Nervous System Diseases (1) · Sleepiness (1)
Sleep Disorders, Intrinsic (9) · Dyssomnias (8) · Mental Disorders (8) · Nervous System Diseases (8) · Sleep Wake Disorders (5) · Disorders of Excessive Somnolence (4) · Neurologic Manifestations (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4)
Takeda (4) · Alkermes, Inc. (3) · Centessa Pharmaceuticals (UK) Limited (3) · Boston Children's Hospital (1) · Northwestern University (1)
United States (11) · Spain (8) · Italy (7) · France (6) · Australia (5) · Japan (4) · Netherlands (4) · Belgium (3) · Canada (3) · China (2) · Czechia (2) · South Korea (2) · Finland (1) · Germany (1) · Norway (1)
Eric Zhou, PhD (1) · Jennifer Mundt, PhD (1)
2025 (1)